Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands
Yansi Wu, Gauthier Quinonez, Ruslan David, Benjamin P. Geisler, Sabine Vogler(Gesundheit Österreich), Oliver Groene, Robin Doeswijk(European Hematology Association), Anne Hendrickx(International Association of Public Transport), Emily A. Burger, Renaud Heine(Erasmus University Rotterdam), Eli Feiring, Tomáš Tesař, Frederick W. Thielen(University Medical Center Freiburg), Mauro Melli, Tom Belleman(Erasmus University Rotterdam), Eline Aas, Carin Uyl-de Groot, Maureen Rutten-van Mölken, Mirjana Huić, Kate Morgan, Pia Sofie Henkel, Isabelle Durand-Zaleski, Marcel Langone Marques, Katie Joyner, Katia Roque Molina, Nina Zimmerman, Nicolas Xander, Lena Jessen, Peter Schneider, Maximilian Salcher‐Konrad(London School of Economics and Political Science)
OSF Preprints (OSF Preprints)
January 15, 2026
Cited by 0
Related Papers
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
Introduction to drug utilization research
|Unknown|2024|211
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3)
|Expert Review of Pharmacoeconomics & Outcomes Research|2016|138